Venus Medtech (HKG:2500) said it is not aware of any undisclosed inside information following media reports about a patent infringement lawsuit involving its U.S. subsidiary, according to a Tuesday Hong Kong bourse filing.
The company made the clarification after the Hong Kong Stock Exchange requested a response to a press article on litigation filed by Cardiovalve and MTH IP against Edwards Lifesciences in a U.S. federal court, the filing said.
Shares of the firm were down more than 6% in Tuesday afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments